Jan. 14, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system ...

Fintel reports that on March 21, 2025, Goldman Sachs upgraded their outlook for Adaptive Biotechnologies (NasdaqGS:ADPT) from Neutral to Buy. As of March 19, 2025, the average one-year price ...

The Goldman Sachs Group upgraded shares of Adaptive Biotechnologies (NASDAQ:ADPT – Free Report) from a neutral rating to a buy rating in a research report released on Friday, Marketbeat.com reports.

Shares of Adaptive Biotechnologies (NASDAQ:ADPT) climbed in the morning hours on Friday after Goldman Sachs upgraded the stock to Buy from Neutral, arguing that the cancer test maker operates in ...

MICHELLE RENEE GRIFFIN, a director at $ADPT, sold 36,291 shares of the company on 03-13-2025 for an estimated $260,932. We received data on the trade from a recent ...

Adaptive Biotechnologies (ADPT) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates ...

Adaptive Biotechnologies Co. (NASDAQ:ADPT – Get Free Report)’s stock price fell 6.1% on Thursday after an insider sold shares in the company.The company traded as low as $7.46 and last traded ...

Adaptive Biotechnologies (ADPT – Research Report) received a Buy rating and price target from Goldman Sachs analyst Matthew Sykes today. The company’s shares closed yesterday at $7.75.

In a report released yesterday, Justin Zelin from BTIG reiterated a Buy rating on Adaptive Biotechnologies (ADPT – Research Report), with a price target of $10.00. The company’s shares closed ...